Q1 2014 13F Holders as of 3/31/2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+11.8M
-
Total reported value, excl. options
-
$373M
-
Value change
-
+$372M
-
Number of buys
-
64
-
Price
-
$31.50
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2014
65 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2014.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 105M outstanding shares and own 11.31% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), Visium Asset Management, LP (898K shares), WADDELL & REED FINANCIAL INC (530K shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (519K shares), MILLENNIUM MANAGEMENT LLC (321K shares), Partner Fund Management, L.P. (321K shares), RS INVESTMENT MANAGEMENT CO LLC (316K shares), FMR LLC (303K shares), Camber Capital Management LLC (300K shares), and Zweig-DiMenna Associates LLC (290K shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.